United We Stand Vs. Divide And Conquer: Pharma In The Age Of Trump
Executive Summary
The pharmaceutical industry fared pretty well in the tumultuous first year of President Trump. But will the industry be able to stay united on key issues in 2018 – or succumb to the divisiveness of the era?
You may also be interested in...
Allergan May Rue Mohawk Tribe Deal As Court Invalidates Restasis Patents
District court questions legitimacy of Allergan's patent transfer tactic, saying it 'could spell the end of the PTO's IPR program.'
Putting The 'Big' Back In PhRMA: New Membership Criteria Pares Ranks
PhRMA eliminates 42% of members in conjunction with new membership eligibility criteria stipulating minimum R&D investment levels.
US FDA Alzheimer Guidance Update Reflects Changes In Biomarkers – And Leadership
Latest update to draft guidance on early Alzheimer’s drug development is the third iteration of a document first published in 2013. The history of the guidance is a reflection of structural and leadership changes in the neurology review team at FDA.